Related Experiment Videos
Disopyramide analysis using REMEDi: comparison with EMIT and conventional high performance liquid chromatographic
V Patel1, P T McCarthy, R J Flanagan
1Poisons Unit, Guy's Hospital, London, UK.
Biomedical Chromatography : BMC
|November 1, 1991
Summary
The REMEDi system, a rapid drug identification tool, effectively measures disopyramide levels in patient samples using high-performance liquid chromatography (HPLC). This automated method is suitable for therapeutic drug monitoring when sufficient sample volume is available.
Area of Science:
- Clinical Chemistry
- Analytical Chemistry
- Pharmacology
Background:
- Therapeutic drug monitoring (TDM) is crucial for optimizing patient outcomes.
- Disopyramide, an antiarrhythmic drug, requires precise quantification for effective treatment.
- Existing analytical methods for drug detection can be time-consuming or require large sample volumes.
Purpose of the Study:
- To evaluate the performance of the REMEDi (Rapid EMErgency Drug identification) automated system for disopyramide analysis.
- To compare REMEDi results with conventional HPLC and EMIT methods.
- To assess the suitability of REMEDi for therapeutic drug monitoring of disopyramide.
Main Methods:
- Automated high-performance liquid chromatography (HPLC) using the REMEDi system.
- Analysis of patient samples (urine, plasma/serum) for disopyramide.
- Comparison with a conventional solvent extraction HPLC method and Enzyme Multiplied Immunoassay Technique (EMIT).
Main Results:
- Good correlation (r=0.91+) between REMEDi and conventional methods.
- REMEDi showed a statistically significant lower mean result compared to EMIT (p<0.01).
- No interference was observed from the primary disopyramide metabolite, mono-N-desalkyldisopyramide.
Conclusions:
- The REMEDi system provides reliable quantification of disopyramide.
- REMEDi is a viable option for therapeutic drug monitoring of disopyramide.
- Sufficient sample volume (0.5-1.0 mL) is a prerequisite for using the REMEDi system.